C Difficile

In this instrumental variable analysis of community-dwelling older adults, longer antibiotic courses were not associated with an increased benefit or harm compared to shorter courses.

This study highlights the significant impact of CDI infections on health outcomes for leukemia patients, emphasizing the need for robust infection control measures, early detection, and aggressive management of CDI to improve patient outcomes and minimize healthcare costs.

Clostridioides difficile is an obligate anaerobic, Gram-positive bacterium that produces toxins. Despite technological progress, conducting gene expression analysis of C. difficile under different conditions continues to be labor-intensive. Therefore, there is a demand for simplified t …

Donor-derived fecal microbiota treatments are efficacious in preventing recurrent Clostridioides difficile infection (rCDI), but they have inherently variable quality attributes, are difficult to scale and harbor the risk of pathogen transfer. In contrast, VE303 is a defined consortium of eight puri …

A hospital pharmacy practice implemented to reduce medication costs may impact vancomycin prescribing at discharge and, in turn, may negatively impact readmission rates for patients with CDI treated with oral vancomycin.

spanbObjectives/b: This systematic review evaluates the effectiveness of fecal microbiota transplantation (FMT) in treating iClostridioides difficile/i infection (CDI) in mouse models using a metabolomics-based approach. bMethods/b: A comprehensive search was conducted in three databases (Pu/span …

Diarrhea associated with enteric infections, gut inflammation, and genetic defects poses a major health burden and results in significant morbidity and mortality. Impaired fluid and electrolyte absorption and/or secretion in the intestine are the hallmark of diarrhea. Electroneutral NaCl absorption …

spaniClostridioides difficile/i is a common etiological factor of hospital infections, which, in extreme cases, can lead to the death of patients. Most strains belonging to this bacterium species synthesize very dangerous toxins: toxin A (TcdA) and B (TcdB) and binary toxin (CDT). The aim of this st/span …

www.clinicaltrials.gov (NCT05430269).

PMC was characterized by a combination of diarrhea, intoxication and abdominal pain. The formation of PMC was preceded by courses of antibacterial drugs of the fluoroquinolone and cephalosporin groups, eradication therapy for iHelicobacter/i infection, the use of high doses of glucocorticosteroi …

Fetal growth restriction (FGR) is a common complication of pregnancy, which seriously endangers fetal health and still lacks effective therapeutic targets. Clostridium difficile (C. difficile) is associated with fetal birth weight, and its membrane vesicles (MVs) are pathogenic vectors. However, the …

BackgroundClostridioides difficile infection (CDI) is a severe infection that needs to be monitored. This infection predominantly occurs in hospitalised patients after antimicrobial treatment, with high mortality in elderly patients.AimWe aimed at estimating the incidence of CDI in Italian ho …

Clostridioides difficile is the leading cause of healthcare- and antibiotic-associated diarrhea. Surface layer protein A (SlpA), an essential component of the bacterium's outermost layer, contributes to colonization and inflammation. The peroxisome proliferator-activated receptor gamma (PPAR-γ) has …

CDI is important because of its frequent occurrence and potential for fatal outcomes. It is crucial to identify patients at risk for recurrence. In our study, the development of CDI attacks in the intensive care unit, malignancy, and continuation of antibiotic treatment for non-CDI infection after C …

Clostridioides difficile is a Gram-positive, spore-forming anaerobic enteropathogen responsible for a wide spectrum of clinical diseases ranging from mild diarrhoea to pseudomembranous colitis. It is the first cause of healthcare-associated diarrhoeas, but community-associated Clostridioides diffici …

Background iClostridium difficile/i infection (CDI) is a significant healthcare concern, marked by its rising prevalence and associated morbidity and mortality. However, there is limited data on the epidemiology of CDI in the eastern region of India. Objectives The study aims to determine the in …

Advancements in Research, Rising Chronic Disease Prevalence, and Regulatory Backing Propel the Global Microbiome Therapeutics Market Forward ...

PCPs from clinics assigned to a low-intensity intervention combining comparative feedback with adverse event notifications had lower antibiotic prescription rates.

Clostridioides difficile (C. difficile) infection (CDI) is a life-threatening healthcare-associated infection occurring worldwide. C. difficile toxins (toxin A and toxin B) are the major virulence factors, causing CDI-related diarrhea and complications. Recent studies have shown that sulfated glycos …

We investigated the intra-hospital distribution of C. difficile strains by whole-genome sequencing (WGS) of isolates collected in 2022 at the University Hospital Centre (UHC) Zagreb. In total, 103 patients with first-episode CDI in 2022 at UHC Zagreb were included, based on the screening stoo …

Nature Microbiology - This Perspective reflects on advances made in the field of human gut microbiome-derived biotherapeutics, from faecal microbiota products to rationally designed second- and...

Xeno Biosciences may have been unable to prove that its drug delivering oxygen to the gastrointestinal tract can induce weight loss, but LPOXY Therapeutics has penned a

Zinplava (bezlotoxumab) injection will be discontinued as of January 31, 2025, according to the FDA’s drug shortages tracker.

Probiotics may help relieve and improve IBS symptoms, like bloating, abdominal pain, and bowel movement irregularity, by balancing the gut’s natural bacteria. Learn more.

Background: Clostridioides difficile (C. difficile) infection (CDI) is the primary cause of antibioticassociated diarrhea. Due to its high resistance rate to...

Scientific Reports - PPAR-γ agonist mitigates intestinal barrier dysfunction and inflammation induced by Clostridioides difficile SlpA in vitro

/PRNewswire/ -- LPOXY Therapeutics, Inc. ("LPOXY"), a clinical-stage biopharmaceutical company focused on innovative therapies for infectious disease...